8-K: ZIVO to Deregister and End SEC Reporting; Execs Exit

ZIVO Bioscience will file Form 15 to suspend SEC reporting and voluntarily delist from OTC markets as part of cost cuts, with its interim CFO and a director resigning.

Summary

• On 2026-03-26, Interim CFO William A. Sullivan announced his intention to resign, effective 2026-03-30.
• On 2026-03-26, Director Alison A. Cornell resigned from the Board and all committees, effective immediately.
• Both resignations are tied to cost-cutting measures, including the decision to deregister securities and cease public reporting, with no disagreements on company matters.
• On 2026-03-27, ZIVO announced plans to file Form 15 on or around 2026-03-30 to deregister its securities, suspend Exchange Act reporting, and voluntarily delist from OTC markets.
• Upon filing Form 15, obligations to file Forms 10-K, 10-Q, and 8-K will immediately cease.
• Management cites significant reductions in legal, accounting, audit, insurance, and administrative costs as a primary rationale, redeploying resources to core operations.
• The CEO anticipates meaningful near-term revenue from the AgTech product line via an established distribution partner and expects positive cash flow for the first time due to lower operating costs.
• Animal Health programs: major global animal health companies are conducting internal due diligence on a non-antibiotic immune-modulating technology; production, yield, dose titration, and interference studies are underway with licensing talks anticipated after data availability.
• Avian Influenza: The University of Georgia plans to use ZIVO’s product in USDA-funded studies addressing poultry industry challenges.
• Governance and alignment: Board compensation has been eliminated; any Board investments occur at full market price; the CEO is investing personal capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views the deregistration/delisting and executive departures as negative for transparency, liquidity, and governance continuity, partially offset by potential near-term revenue and cost savings.

Positives

• Material cost savings expected from eliminating SEC reporting, audit, insurance, and OTC listing-related expenses, freeing capital for R&D and commercialization.
• Management focus shifts to core Animal Health and AgTech/Human Nutrition operations.
• Anticipated meaningful revenue in the coming months via a distribution partner for the AgTech product line.
• Management expects positive cash flow for the first time due to revenue ramp and lower operating costs.
• Active engagement by major global animal health companies with internal due diligence and potential licensing once current studies conclude.
• Inclusion of ZIVO’s product in USDA-funded Avian Influenza studies at the University of Georgia supports external validation and visibility.
• Board compensation eliminated; directors and CEO signal alignment by investing at full market price and with personal capital.

Negatives

• Voluntary deregistration and OTC market delisting will end SEC reporting, likely reducing transparency, research coverage, and trading liquidity.
• Loss of Interim CFO and an independent director, which may strain finance and governance capacity during a transition.
• Revenue remains early-stage with no quantified guidance, timing, or margins disclosed.
• History of repeated capital raises and dilution; ability to fund operations remains a disclosed risk.

Risks

• Strategic partnerships may not facilitate commercialization or market acceptance of products.
• Inability to increase production sufficient to meet demand.
• Products may not be ready for commercialization in a timely manner or at all.
• Products may not perform as expected based on results of preclinical and clinical trials.
• Ability to raise additional funds remains uncertain.
• Uncertainties inherent in product development processes.
• Changes in regulatory requirements or decisions of regulatory authorities.
• Uncertainty around the size and growth potential of target markets.
• Outcomes of clinical trials may differ from expectations.
• Ability to protect intellectual property rights.

Future Outlook

Management plans to file Form 15 on or around March 30, 2026 to suspend SEC reporting, redirect resources to Animal Health and AgTech/Human Nutrition, ramp near-term revenue through a distribution partner, aim for positive cash flow, complete ongoing production and dosing studies, and pursue partnership/licensing discussions once supporting data are available while increasing production capacity to meet anticipated demand.

Management Comments

• “Simply put, too much of our capital is flowing to third parties to sustain our public status rather than being deployed to build the business and create value for you, our shareholders.”
• Remaining a public reporting company is no longer in shareholders’ best interests at this stage due to disproportionate compliance costs and dilution from repeated capital raises.
• Management anticipates meaningful revenue from the AgTech product line in the coming months through an established distribution partner, positioning the company for positive cash flow.
• Major animal health companies are advancing internal due diligence; production, yield, dose titration and interference studies are underway, with licensing talks expected once data are available.
• Board compensation has been eliminated; any Board investments are at full market price; the CEO continues to invest personal capital.

Industry Context

StockSavvy.ai notes that voluntary deregistration is a common cash-preservation step among thinly capitalized micro-cap R&D companies, but it typically reduces transparency and liquidity. In animal health, partnering with large strategics (e.g., leading veterinary pharma firms) is a conventional path to commercialization; however, partners generally require robust data packages (dose optimization, scale-up, field validation) before licensing. Interest in non-antibiotic immune modulation and avian influenza solutions remains elevated industry-wide, which could support ZIVO’s partnering narrative if forthcoming data are positive.

Comparison to Industry Standards

• Voluntary deregistration is atypical relative to most micro-cap biotech and agtech peers that maintain SEC reporting to access public capital; it generally signals a stronger emphasis on cost control over capital market optionality.
• Animal health product commercialization frequently relies on partnerships with large strategics (e.g., Zoetis, Elanco, Merck Animal Health); industry practice is to advance to licensing only after successful dose-ranging, manufacturing scale-up, and field studies—benchmarks ZIVO indicates are in progress but not yet completed.
• Microalgae-derived nutrition and functional ingredients compete in markets where established suppliers prioritize consistent scale, quality, and regulatory clarity; without disclosed production economics or margins, ZIVO’s pathway to competitive unit economics remains to be demonstrated versus industry norms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: loss of SEC reporting transparency and likely reduced liquidity following OTC delisting; potential benefit from lower cash burn and path to positive cash flow.
• Employees: greater resource focus on core R&D, production scale-up, and commercialization efforts.
• Customers/Partners: potential for improved execution focus; however, reduced public disclosures may limit visibility into progress.
• Creditors/Suppliers: cost reductions and prospective positive cash flow could improve counterparty risk profile.
• Warrant/Equity holders: trading venue changes and lower liquidity may affect price discovery and exit optionality.

Next Steps

• File Form 15 on or around 2026-03-30 to suspend SEC reporting obligations.
• Cease filing Forms 10-K, 10-Q, and 8-K immediately upon Form 15 effectiveness.
• Advance production, yield, dose titration, and interference studies in Animal Health to support partnership/licensing discussions.
• Support University of Georgia studies utilizing the company’s product in USDA-funded Avian Influenza research.
• Increase production capacity to meet anticipated demand for ZIVO LIFE microalgae ingredient.
• Provide further business updates to shareholders in the coming weeks.

Key Dates

Recommendation

Voluntary deregistration and OTC delisting, coupled with the loss of an interim CFO and a director, increase risk by reducing transparency, liquidity, and governance depth. While cost savings and prospective near-term revenue are positives, the absence of quantified financial guidance, continued development and partnering risks, and a history of dilution tilt the risk-reward unfavorably based solely on this announcement.

Keywords

Form 15 deregistration, End SEC reporting, OTCQB delisting, ZIVO Bioscience, cost-cutting, CFO resignation, director resignation, animal health, agtech, microalgae, non-antibiotic immune modulation, distribution partner, positive cash flow, Avian Influenza, USDA, University of Georgia, licensing, due diligence, shareholder dilution, board compensation